R
Rosette Lidereau
Researcher at Curie Institute
Publications - 286
Citations - 25158
Rosette Lidereau is an academic researcher from Curie Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 78, co-authored 281 publications receiving 23689 citations. Previous affiliations of Rosette Lidereau include French Institute of Health and Medical Research & PSL Research University.
Papers
More filters
Journal ArticleDOI
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Michel Obeid,Michel Obeid,Michel Obeid,Carla Ortiz,Carla Ortiz,Carla Ortiz,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,M. Chiara Maiuri,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Patrick Saulnier,Huan Yang,Sebastian Amigorena,Bernard Ryffel,Franck J. Barrat,Paul Saftig,Francis Lévi,Francis Lévi,Rosette Lidereau,Catherine Noguès,Jean-Paul Mira,Agnès Chompret,Virginie Joulin,Françoise Clavel-Chapelon,Jean Bourhis,Fabrice Andre,Suzette Delaloge,T. Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +42 more
TL;DR: A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.
Journal ArticleDOI
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
François Ghiringhelli,Lionel Apetoh,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Laetitia Aymeric,Laetitia Aymeric,Laetitia Aymeric,Yuting Ma,Yuting Ma,Yuting Ma,Carla Ortiz,Karim Vermaelen,Theocharis Panaretakis,Theocharis Panaretakis,Theocharis Panaretakis,Grégoire Mignot,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Jean-Luc Perfettini,Jean-Luc Perfettini,Jean-Luc Perfettini,Frédéric Schlemmer,Frédéric Schlemmer,Frédéric Schlemmer,Ezgi Tasdemir,Ezgi Tasdemir,Ezgi Tasdemir,Martin Uhl,Pierre Génin,Ahmet Civas,Bernhard Ryffel,Jean Kanellopoulos,Jürg Tschopp,Fabrice Andre,Fabrice Andre,Fabrice Andre,Rosette Lidereau,Nicole McLaughlin,Nicole M. Haynes,Mark J. Smyth,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +45 more
TL;DR: It is shown that dying tumor cells release ATP, which then acts on P2X7 purinergic receptors from DCs and triggers the NOD-like receptor family, pyrin domain containing-3 protein (NLRP3)-dependent caspase-1 activation complex ('inflammasome'), allowing for the secretion of interleukin-1 β (IL-1β).
Journal ArticleDOI
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
Marc Buyse,Sherene Loi,Laura J. van't Veer,Giuseppe Viale,Mauro Delorenzi,Annuska M. Glas,Mahasti Saghatchian d'Assignies,Jonas Bergh,Rosette Lidereau,Paul Ellis,Adrian L. Harris,Jan Bogaerts,Patrick Therasse,Arno Floore,Mohamed Amakrane,Fanny Piette,Emiel J. Th. Rutgers,Christos Sotiriou,Fatima Cardoso,Martine Piccart +19 more
TL;DR: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer and outperformed the clinicopathological risk assessment in predicting all endpoints.
Journal ArticleDOI
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,
Christine Desmedt,Fanny Piette,Sherene Loi,Yixin Wang,Françoise Lallemand,Benjamin Haibe-Kains,Giuseppe Viale,Mauro Delorenzi,Yi Zhang,Mahasti Saghatchian d'Assignies,Jonas Bergh,Rosette Lidereau,Paul Ellis,Adrian L. Harris,Jan Klijn,John A. Foekens,Fatima Cardoso,Martine Piccart,Marc Buyse,Christos Sotiriou +19 more
TL;DR: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases.
Journal ArticleDOI
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Carla Ortiz,Carla Ortiz,Carla Ortiz,Rosette Lidereau,Christophe Mariette,Nathalie Chaput,Nathalie Chaput,Jean-Paul Mira,Suzette Delaloge,Fabrice Andre,Thomas Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +22 more
TL;DR: It is shown that the release of the high mobility group box 1 protein by dying tumor cells is mandatory to license host dendritic cells (DCs) to process and present tumor antigens, and this knowledge may be clinically exploited to predict the immunogenicity and hence the efficacy of chemotherapeutic regimens.